CN109400709A - Bifunctional antibody and application thereof - Google Patents
Bifunctional antibody and application thereof Download PDFInfo
- Publication number
- CN109400709A CN109400709A CN201811283836.1A CN201811283836A CN109400709A CN 109400709 A CN109400709 A CN 109400709A CN 201811283836 A CN201811283836 A CN 201811283836A CN 109400709 A CN109400709 A CN 109400709A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- val
- thr
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention provides a kind of bifunctional antibody, is the divisional application of Chinese patent 201510782939.2.Bifunctional antibody of the invention can be specifically bound with humanTNF-α；It can be specifically bound simultaneously with people P40.Bifunctional antibody can highly desirable block the combination of people's IL-12 and IL-12 receptor, block the combination of humanTNF-α and TNF-α receptor.Bifunctional antibody of the present invention can be in combination with humanTNF-α and people's P40 albumen, the combination of TNF-α and IL-12 and corresponding receptor can be effectively inhibited, to inhibit the secretion of inflammatory cytokine and IFNgamma molecule respectively, can be used in treating rheumatoid arthritis, chronic plaque psoriasis, moderate to severe Crohn disease, moderate to severe refractory ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe joint type juvenile idiopathic arthritis, Crohn disease pediatric patients.
Description
The application is Chinese November 13 2015 applying date, and application number 201510782939.2 is entitled " difunctional anti-
The divisional application of body and application thereof ".
Technical field
The present invention relates to antibody, and in particular to can block the combination of humanTNF-α and TNF-α receptor simultaneously and block people
The bifunctional antibody of the combination of IL-12 and IL-12 receptor.
Background technique
Humira (Adalimumab) is the full humanization tumor necrosis factor of recombination expressed in Chinese hamster ovary cell
Sub- alpha monoclonal antibodies.In addition to moderate to severe rheumatoid arthritis, the indication of FDA approved further includes moderate to severe
Chronic plaque psoriasis, moderate to severe Crohn disease, moderate to severe refractory ulcerative colitis, ankylosing spondylitis, silver bits
Sick arthritis, moderate to severe joint type juvenile idiopathic arthritis, the therapeutical uses of Crohn disease pediatric patients.2013
Year, in global ten big best seller brand drugs, adalimumab sales volume is 106.6 hundred million dollars, growth rate 15.0%, ranking
First.
Monoclonal antibody medicine Stelara (ustekinumab) acts on the common subunit P40 of IL-12 and IL-23, passes through blocking
The downstream signaling pathway of IL-12 and IL-23 is antipsoriatic to play the role of.Stelara is in 2009 by U.S. FDA batch
Standard, for treating severe psoriasis in adult.One for moderate to severe psoriatic's III phase clinical studies show,
P40 monoclonal antibody has more treatment advantage, and required frequency injection is far fewer than Etanercept.According to the 17th meeting of institute, Dermatology European Section
View report: receiving p40 monoclonal antibody (two groups of low dosage 45mg and high dose 90mg) respectively and Etanercept control within 12 weeks by a definite date
It treats, p40 monoclonal antibody group starts in treatment and the 4th week is administered 2 times altogether, Etanercept group weekly administration 2 times.The results show that psoriasis
It is respectively 68% and 74% that severity remission rate, which reaches 75%, p40 monoclonal antibody 45mg and 90mg dosage group, and Etanercept group
It is 57%.
The action target spot of monoclonal antibody is and a large amount of complex disease for some single target spot, such as tumour, class wind
There are many machines of falling ill for wet arthritis, tumour, autoimmunity disease, the organ complications of metabolic disease, degenerative diseases of aged etc.
System, and various pathogenesis can influence each other, it is sometimes network-like, the generation of disease is resulted in jointly.For a certain disease list
The monoclonal antibody limited efficacy of one target spot.Bifunctional antibody is to pathogenesis (signal most important during this disease incidence
Access) intervene simultaneously, it is expected to obtain the addition or collaboration of drug effect, obtains preferably clinical efficacy.Simultaneously for TNF-α and P40
Intervene and block, is expected to obtain preferably curative effect relative to the interference of single target spot in terms of curing psoriasis.Therefore it needs at present
The bifunctional antibody of exploitation while antagonism TNF-α and anti-P40.
Summary of the invention
Three kinds of bifunctional antibodies are provided it is an object of the invention to overcome the shortcomings of the prior art place, it is described
Three kinds of antibody can block the combination of humanTNF-α and TNF-α receptor, moreover it is possible to the combination of people's IL-12 and IL-12 receptor is blocked, this
Invention also provides the purposes of three kinds of bifunctional antibodies.
To achieve the above object, the technical solution taken: a kind of bifunctional antibody, the bifunctional antibody include 2
Identical light chain and 2 identical heavy chains, the amino acid sequence of the light chain is as shown in SEQ ID NO.1, the ammonia of the heavy chain
Base acid sequence is as shown in SEQ ID NO.2.Bifunctional antibody described here is named as bifunctional antibody BIAU003.
A kind of bifunctional antibody, the bifunctional antibody includes 2 identical light chains and 2 identical heavy chains, described light
The amino acid sequence of chain is as shown in SEQ ID NO.4, and the amino acid sequence of the heavy chain is as shown in SEQ ID NO.3.It will here
The bifunctional antibody is named as bifunctional antibody BIAU022.
A kind of bifunctional antibody, the bifunctional antibody includes 2 identical light chains and 2 identical heavy chains, described light
The amino acid sequence of chain is as shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is as shown in SEQ ID NO.5.It will here
The bifunctional antibody is named as bifunctional antibody BIAU023.
The present invention provides three kinds of bifunctional antibodies described above in preparation for blocking humanTNF-α and TNF-α receptor
Combination and/or block people's IL-12 and IL-12 receptor combination preparation in purposes.
The present invention also provides three kinds of bifunctional antibodies described above to treat rheumatoid arthritis, chronic spot in preparation
Block psoriasis pustulosa, moderate to severe Crohn disease, moderate to severe refractory ulcerative colitis, ankylosing spondylitis, psoriasis arthropathica
Purposes scorching, in moderate to the drug of severe joint type juvenile idiopathic arthritis or Crohn disease pediatric patients.
The beneficial effects of the present invention are: the present invention provides a kind of three kinds of bifunctional antibodies, and of the invention 3 kinds are difunctional
Antibody can be specifically bound with humanTNF-α；3 kinds of bifunctional antibodies can be specifically bound with people P40 simultaneously.Described three kinds double
Function antibody can highly desirable block the combination of people's IL-12 and IL-12 receptor, and can highly desirable block
The combination of humanTNF-α and TNF-α receptor.3 kinds of bifunctional antibodies of the invention can in combination with humanTNF-α and people's P40 albumen,
The combination of TNF-α and IL-12 and corresponding receptor can be effectively inhibited, to inhibit inflammatory cytokine and IFNgamma points respectively
The secretion of son can be used in treating rheumatoid arthritis, chronic plaque psoriasis, moderate to severe Crohn disease, moderate
To severe refractory ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe joint type Juvenile idiopathic joint
Scorching, Crohn disease pediatric patients.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of bifunctional antibody BIAU003 of the present invention；
Fig. 2 is the structural schematic diagram of bifunctional antibody BIAU022 of the present invention；
Fig. 3 is the structural schematic diagram of bifunctional antibody BIAU023 of the present invention；
Fig. 4 be in the embodiment of the present invention 4 ELISA method detect bifunctional antibody BIAU003, BIAU022 of the present invention and
BIAU023 is to the binding ability (A) of p40, and the result to TNF-α binding ability (B)；
Fig. 5 is bifunctional antibody BIAU003, BIAU022 and BIAU023 inhibition TNF-α of the present invention in the embodiment of the present invention 5
The result of the cell surface adhesion molecule ELAM-1 expression of induction；
Fig. 6 is bifunctional antibody BIAU003, BIAU022 and BIAU023 inhibition IL-12 of the present invention in the embodiment of the present invention 6
The result of the IFNgamma secretion of induction；
Fig. 7 is the suppression of bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention to psoriasis mice pachyderma
Result processed.
Specific embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment to the present invention
It is described further.The amino acid sequence of the light chain of bifunctional antibody BIAU003 of the present invention as shown in SEQ ID NO.1,
The amino acid sequence of the heavy chain of the bifunctional antibody BIAU003 is as shown in SEQ ID NO.2；Bifunctional antibody of the present invention
The amino acid sequence of the light chain of BIAU022 is as shown in SEQ ID NO.4, the amino of the heavy chain of the bifunctional antibody BIAU003
Acid sequence is as shown in SEQ ID NO.3；The amino acid sequence of the light chain of bifunctional antibody BIAU003 of the present invention such as SEQ ID
Shown in NO.1, the amino acid sequence of the heavy chain of the bifunctional antibody BIAU003 is as shown in SEQ ID NO.5.
The structural schematic diagram of bifunctional antibody BIAU003 of the present invention is as shown in Figure 1, wherein heavy chain is by following part structure
At: the heavy chain variable region of first antibody-first antibody heavy chain constant region-GGGGS amino acid linker- secondary antibody weight chain variable
Area -- GGGGS amino acid linker- secondary antibody light chain variable region；That is the entire heavy chain of first antibody and secondary antibody heavy chain can
Become area-secondary antibody light chain variable region to connect by amino acid.Light chain consists of the following parts: first antibody it is complete light
Chain.
The structural schematic diagram of bifunctional antibody BIAU022 of the present invention is as shown in Fig. 2, wherein heavy chain is by following part structure
At: heavy chain variable region-GGGGS amino acid linker- first antibody heavy chain variable region-first antibody light chain constant of secondary antibody
Area；I.e. the heavy chain variable region of secondary antibody is connected with first antibody entire heavy chain by amino acid.Light chain is by following part
Constitute: the light chain variable region-GGGGS amino acid linker- first antibody light chain variable region of secondary antibody-first antibody light chain is permanent
Determine area；I.e. the light chain variable region of secondary antibody is connected with first antibody Whole light chains by amino acid.
The structural schematic diagram of bifunctional antibody BIAU023 of the present invention is as shown in figure 3, wherein heavy chain is by following part structure
At: entire heavy chain-GGGGS amino acid linker- secondary antibody heavy chain variable region-secondary antibody chain constant of first antibody
Area-GGGGS amino acid linker- secondary antibody light chain variable region-secondary antibody heavy chain constant region 1；Light chain is by following part structure
At: first antibody Whole light chains.
Embodiment 1: the albumen preparation of bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention
It is artificial respectively according to the heavy chain and light-chain amino acid sequence of bifunctional antibody BIAU003, BIAU022 and BIAU023
Synthesize the heavy chain of bifunctional antibody BIAU003, BIAU022 and BIAU023 and the cDNA of light chain.All equal codons of cDNA
Optimization, can be used for mammalian cell expression.The cDNA of synthesis is cloned into respectively in pcDNA3.1 plasmid, and true by sequencing
It is correct to determine plasmid construction.The plasmid conversion TOP10 bacterial strain being sequenced, picking single colonie are inoculated into 0.5 liter of LB liquid medium,
When to OD600 being 0.8, thalline were collected by centrifugation, extracts plasmid with the big extraction reagent kit of plasmid (be purchased from Qiagen company).Sequencing is reflected
The plasmid of the fixed light chain correctly containing bifunctional antibody BIAU003 and sequencing identification correctly contain bifunctional antibody
The plasmid co-transfection of the heavy chain of BIAU003 correctly contains bifunctional antibody into the same 293F cell, by sequencing identification
The plasmid co-transfection of heavy chain of the plasmid and sequencing identification of the light chain of BIAU022 correctly containing bifunctional antibody BIAU022 arrives
In another 293F cell, the plasmid of the light chain by sequencing identification correctly containing bifunctional antibody BIAU023 and sequencing are identified
The plasmid co-transfection of heavy chain correctly containing bifunctional antibody BIAU023 is into another 293F cell.Transfect cell culture
Condition is 37 degree, 5%CO2,130rpm/min.After culture 7 days, supernatant is collected by centrifugation.Supernatant 6000rpm is centrifuged 10min, and
With 0.45 μm of membrane filtration, filtrate is collected；500mM NaCl is added in filtrate；Adjust PH to 7.4.Sample through 0.2 μm of filter membrane again
After filtering, loading to the HiTrap MabSelect column balanced with PBS (purchased from GE company)；PBS is used after complete on sample
It rinses, flow velocity 5ml/min, ultraviolet monitoring is level.Then with elution Buffer (0.5M Glycine, pH 3.0) elution, stream
Fast 1ml/min collects eluting peak with Tris and is neutralized to pH 7.4.Eluting peak is concentrated with pipe is concentrated by ultrafiltration, changes buffering with desalting column
Thus solution obtains BIAU003, BIAU022, BIAU023 totally 3 kinds of bifunctional antibodies into PBS.
Embodiment 2:SPR measures the combination antigenic capacity of bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention
By SPR analysis (being purchased from GE company) to p40 and TNF-α affinity and binding kinetics.Utilize standard amine coupling
P40 or TNF-α are covalently attached to chip (carboxymethyl dextran coating through primary amine by chemistry and the chip provided by GE company
Chip).Using biotin labeling reagent box (Pierce company) by recombination fusion protein and biotin covalent coupling, then flow
The SA chip (purchased from GE company) for crossing Avidin label, makes response value RU reach 450.By by antibody with 0.01,0.03,
0.09, the flow velocity of 0.27 μM of concentration and 50 μ l/min flow in PBS buffer solution and measure association and dissociation constant.Tracking is anti-
Antigen-antibody binding kinetics 3 minutes simultaneously track Dissociation 10 minutes.It will be in conjunction with reconciliation using BIAEvaluation software
From curve matching to 1: 1 Lang Gemiaoer (Langmuir) binding model, measurement result shows: BIAU003, BIAU022,
BIAU023 can combine p40 and TNF-α.Kd, Kon and Koff value of measurement the results are shown in Table one and table two.
One SPR of table measures bifunctional antibody combination antigen p40 capability result of the present invention
| Antibody Designation | Kon(105M-1S-1) | Koff(10-5S-1) | Kd(nm) |
| BIAU003 | 1.87 | 2.02 | 0.11 |
| BIAU022 | 1.74 | 2.19 | 0.13 |
| BIAU023 | 0.87 | 2.96 | 0.34 |
Two SPR of table measures bifunctional antibody combination antigen TNF-α capability result of the present invention
Embodiment 3: competitive ELISA method measure bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention and
TNF-α Receptor Competition combination antigen TNF-α
With TNF-α-mFc coated elisa plate, 1%BSA closing, respectively by antibody BIAU003, BIAU022 of various concentration,
BIAU023 is mixed with TNF-α receptor-hFc, is added 37 DEG C of ELIAS secondary antibody after 37 DEG C of incubations and is incubated for 30 minutes.It is examined in microplate reader
Survey the light absorption value of 450nm.Bifunctional antibody in conjunction with antigen TNF-α the results show that bifunctional antibody BIAU003 of the present invention,
BIAU022, BIAU023 can the effectively TNF-α albumen in conjunction with TNF-α Receptor Competition, and its joint efficiency in dosage according to
The relationship of relying.By the competitive ELISA interpretation of result of the bifunctional antibody to combination, curve simulation bifunctional antibody BIAU003,
The antagonism TNF-α receptor and antigen TNF-α joint efficiency IC50 of BIAU022, BIAU023 be respectively as follows: 0.5nm, 2.3nm,
1.8nm。
Embodiment 4: bifunctional antibody BIAU003, BIAU022 and BIAU023 combination antigenic capacity detection of the present invention
4 valence bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention can be targeted in combination with p40 and TNF-α egg
It is white.Experiment is using ELISA method detection bifunctional antibody to the binding ability of this two antigens.It is coated with 2ug/ml respectively first
Antigen, 4 degree of coatings overnight, after wash 3 unbonded antigens of removal with PBST, are directly added into the difunctional of various concentration and resist
Body is incubated at room temperature 2 hours.After incubation, PBST is washed 3 times, to clean the antibody for removing to be not bound with antigen.Then it is added anti-
The secondary antibody (HRP label) of His tag label is incubated for 1 hour.After PBST is cleaned 3 times, is developed the color with DAB method, then use multifunctional enzyme
Mark instrument is read.If Fig. 4 data are shown, bifunctional antibody BIAU003, BIAU022 and BIAU023 and positive antibody of the present invention
All have to the very strong binding ability of respective antigen (it is in conjunction with TNF-α that Fig. 4 A, which is in conjunction with p40, Fig. 4 B).
Embodiment 5: bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention inhibit ELAM-1 protein expression
Cell surface adhesion molecule ELAM-1 expression is regulated and controled by TNF-α, and the regulation of adhesion molecule is TNF-α biological effect
Important embodiment.This experimental study block TNF-α access after, cell express ELAM-1 albumen the case where.It is inoculated with 2 × 105/ holes
HUVEC cell is in 6 orifice plates, after cell is adherent, is separately added into the bifunctional antibody of the present invention of 10ng/ml and various concentration
BIAU003, BIAU022 and BIAU023 are subsequently placed in cell incubator and continue culture for 24 hours.After for 24 hours, trypsin digestion cell is simultaneously
It is washed and is placed on ice with PBS, the anti-ELAM-1 antibody of FITC label is then added, be incubated for 30min.Then flow cytometer is used
Cell surface fluorescence intensive analysis is carried out, the fluorescence intensity data of flow cytometer is converted and mapped with Prism software.
As bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention can block TNF-α to induce to Fig. 5 completely as the result is shown
ELAM-1 protein expression, the degree of blocking and bifunctional antibody concentration have dose-dependence (Fig. 5)
Embodiment 6: bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention inhibit the secretion of IFNgamma
Bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention can target the p40 of combination cell factor IL-12
Subunit, to inhibit the biological function of IL-20.This experiment detect bifunctional antibody BIAU003, BIAU022 of the present invention and
The IFNgamma expression that can BIAU023 inhibit IL-12 to regulate and control.The T cell of purifying is in the culture medium of factor-containing IL-2
Culture is activated and is proliferated for 3 days, at the 4th day, T cell is inoculated in 96 orifice plates by the density in 1 × 105/ hole, by the dense of setting
Bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention is added in degree.It is subsequently placed in 37 degree of carbon dioxide incubator cultures
24 hours.Cell culture medium, centrifuging and taking supernatant are collected after 24 hours.10ul supernatant is taken to carry out IFNgamma quantitative analysis, according to
The illustration method of quantification kit is tested, and experimental result is read with multi-function microplate reader.Such as Fig. 6 the result shows that T is thin
Born of the same parents significantly secrete IFNgamma under IL-2 and IL-12 effect, right with the increase of bifunctional antibody concentration of the present invention
The secretion inhibition of IFNgamma is more obvious, and individually IL-2 stimulation can not inducing T cell secretion IFNgamma (Fig. 6)
Embodiment 7: the drug effect of bifunctional antibody BIAU003, BIAU022 and BIAU023 of the present invention to psoriasis mice
Using DBA-1 mouse, dorsal sc injection rHuIL-12 (30ug) union and recombination humanTNF-α (10ug) induction
Mouse generates psoriatic lesions.BiAU003, BiAU022, BiAU023 are given within 1 day before people IL-12 and TNF-α is subcutaneously injected for the first time
20mg/kg, continuous injection 3 days, takes skin of back to fix on the 4th day, observes psoriasis mice epidermal thickness after HE dyeing.
Mouse skin thickness is as shown in Figure 7.As seen from the figure, BiAU003, BiAU022, BiAU023 can be effectively reduced
Mouse skin thickness, drug effect are better than independent Ustekinumab and Adalimumab group.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
Sequence table
<110>Ye Caiguo
<120>bifunctional antibody and application thereof
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 214
<212> PRT
<213>artificial sequence
<400> 1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ile Tyr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 2
<211> 718
<212> PRT
<213>artificial sequence
<400> 2
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr
20 25 30
Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Asp Trp Ile
35 40 45
Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ser Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
450 455 460
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
465 470 475 480
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
485 490 495
Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys
500 505 510
Cys Leu Glu Trp Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp
515 520 525
Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
530 535 540
Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
545 550 555 560
Ala Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser
565 570 575
Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
580 585 590
Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
595 600 605
Gly Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
610 615 620
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg
625 630 635 640
Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
645 650 655
Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe
660 665 670
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
675 680 685
Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala
690 695 700
Pro Tyr Thr Phe Gly Gln Cys Thr Lys Val Glu Ile Lys Arg
705 710 715
<210> 3
<211> 581
<212> PRT
<213>artificial sequence
<400> 3
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Gly Pro Lys Gly
115 120 125
Gly Gly Gly Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
130 135 140
Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser
145 150 155 160
Phe Thr Thr Tyr Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly
165 170 175
Leu Asp Trp Ile Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr
180 185 190
Ser Pro Ser Phe Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile
195 200 205
Thr Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala
210 215 220
Met Tyr Tyr Cys Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe
225 230 235 240
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ser Thr Lys Gly
245 250 255
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
260 265 270
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
275 280 285
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
290 295 300
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
305 310 315 320
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
325 330 335
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
340 345 350
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
355 360 365
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
370 375 380
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
385 390 395 400
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
405 410 415
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
420 425 430
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
435 440 445
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
450 455 460
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
465 470 475 480
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
485 490 495
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
500 505 510
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
515 520 525
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
530 535 540
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
545 550 555 560
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
565 570 575
Leu Ser Pro Gly Lys
580
<210> 4
<211> 332
<212> PRT
<213>artificial sequence
<400> 4
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
115 120 125
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
130 135 140
Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
145 150 155 160
Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val
165 170 175
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
180 185 190
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
195 200 205
Tyr Asn Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
210 215 220
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
225 230 235 240
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
245 250 255
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
260 265 270
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
275 280 285
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
290 295 300
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
305 310 315 320
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
325 330
<210> 5
<211> 945
<212> PRT
<213>artificial sequence
<400> 5
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr
20 25 30
Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Asp Trp Ile
35 40 45
Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ser Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
450 455 460
Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
465 470 475 480
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
485 490 495
Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys
500 505 510
Gly Leu Glu Trp Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp
515 520 525
Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
530 535 540
Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
545 550 555 560
Ala Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser
565 570 575
Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
580 585 590
Val Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
595 600 605
Gln Ala Asn Lys Ala Thr Leu Val Cys Tyr Ile Ser Asp Phe Tyr Pro
610 615 620
Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
625 630 635 640
Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
645 650 655
Ala Trp Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
660 665 670
Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
675 680 685
Val Ala Pro Thr Glu Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
690 695 700
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
705 710 715 720
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
725 730 735
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
740 745 750
Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala
755 760 765
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
770 775 780
Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
785 790 795 800
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp
805 810 815
Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr Thr Phe
820 825 830
Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Ser Ala Ser Thr Lys Gly
835 840 845
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
850 855 860
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
865 870 875 880
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val Ala Thr Gly
885 890 895
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
900 905 910
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
915 920 925
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
930 935 940
Ser
945
Claims (3)
1. a kind of bifunctional antibody, which is characterized in that the bifunctional antibody includes 2 identical light chains and 2 identical heavy
Chain, the amino acid sequence of the light chain is as shown in SEQ ID NO.1, the amino acid sequence of the heavy chain such as SEQ ID NO.5 institute
Show.
2. bifunctional antibody as claimed in claim 2 preparation for block humanTNF-α and TNF-α receptor combination and/or
Block the purposes in the preparation of the combination of people's IL-12 and IL-12 receptor.
3. bifunctional antibody as claimed in claim 2 preparation treatment rheumatoid arthritis, chronic plaque psoriasis, in
It spends to severe Crohn disease, moderate to severe refractory ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe
Purposes in the drug of joint type juvenile idiopathic arthritis or Crohn disease pediatric patients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811283836.1A CN109400709B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibodies and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811283836.1A CN109400709B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibodies and uses thereof |
| CN201510782939.2A CN105294863B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510782939.2A Division CN105294863B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109400709A true CN109400709A (en) | 2019-03-01 |
| CN109400709B CN109400709B (en) | 2021-03-23 |
Family
ID=55192761
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510782939.2A Active CN105294863B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
| CN201811283836.1A Active CN109400709B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibodies and uses thereof |
| CN201811282587.4A Pending CN109293777A (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510782939.2A Active CN105294863B (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811282587.4A Pending CN109293777A (en) | 2015-11-13 | 2015-11-13 | Bifunctional antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105294863B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021018114A1 (en) * | 2019-07-30 | 2021-02-04 | 中山康方生物医药有限公司 | Anti-human p40 protein domain antibody and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| CN102458471A (en) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | Antigen-binding proteins |
| CN103251945A (en) * | 2004-04-09 | 2013-08-21 | 艾博特生物技术有限公司 | Multiple-variable dose regimen for treating tnfalpha-related disorders |
| CN103562221A (en) * | 2011-03-28 | 2014-02-05 | 赛诺菲 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
-
2015
- 2015-11-13 CN CN201510782939.2A patent/CN105294863B/en active Active
- 2015-11-13 CN CN201811283836.1A patent/CN109400709B/en active Active
- 2015-11-13 CN CN201811282587.4A patent/CN109293777A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251945A (en) * | 2004-04-09 | 2013-08-21 | 艾博特生物技术有限公司 | Multiple-variable dose regimen for treating tnfalpha-related disorders |
| WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| CN102458471A (en) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | Antigen-binding proteins |
| CN103562221A (en) * | 2011-03-28 | 2014-02-05 | 赛诺菲 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
Non-Patent Citations (2)
| Title |
|---|
| KONTERMANN,RE等: "Dual targeting strategies with bispecific antibodies", 《MABS》 * |
| VALLERA D A等: "Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases", 《MOLECULAR CANCER THERAPEUTICS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021018114A1 (en) * | 2019-07-30 | 2021-02-04 | 中山康方生物医药有限公司 | Anti-human p40 protein domain antibody and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109293777A (en) | 2019-02-01 |
| CN105294863B (en) | 2019-01-22 |
| CN109400709B (en) | 2021-03-23 |
| CN105294863A (en) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107686520A (en) | Anti- PD L1 nano antibodies and its application | |
| CN109096395A (en) | Blocking-up type CD47 nano antibody and application thereof | |
| CN110041433A (en) | A kind of Chimeric antigen receptor and its application targeting BCMA | |
| US20220002408A1 (en) | Bispecific antibody, preparation method thereof and application thereof | |
| CN106939047A (en) | A kind of PD-L1 antibody and preparation method thereof | |
| CN106699888A (en) | PD (Programmed Cell Death)-1 antibody as well as preparation method and application thereof | |
| CN109096396A (en) | A kind of anti-PD-L1 humanization nano antibody and its application | |
| CN107216389A (en) | Anti- PD-L1 nano antibodies and its coded sequence and purposes | |
| CN111647082B (en) | Antibodies against human IL-4RA and uses thereof | |
| CN101037671B (en) | Hybridoma cell line and anti-human erythrocyte surface H antigen monoclonal antibodies generated thereof | |
| CN101495632A (en) | Humanized anti-human osteopontin antibody | |
| US20210070875A1 (en) | Anti-c5ar antibody and preparation method and use thereof | |
| CN110144011A (en) | For the single domain antibody of T lymphocyte immunoglobulin Mucin 3 | |
| CN107001464A (en) | Anti- tenascin C antibody and its purposes | |
| CN109306017B (en) | Recombinant protein prepared based on SIRP-alpha D1 mutant and application thereof | |
| CN101062949B (en) | Recombinant anti human IgE monoclonal antibody and preparation method and usage thereof | |
| CN109897107A (en) | Nano antibody and preparation method thereof | |
| CN100362018C (en) | Recombinant monoclonal antibody against EGFR | |
| CN102702323A (en) | Application of procalcitonin B cell epitope peptide fragment and monoclonal antibody thereof | |
| CN105294863B (en) | Bifunctional antibody and application thereof | |
| CN107964045A (en) | A kind of full molecule IgG of people mouse inosculating antibody CXCR2 and its application | |
| CN108635579A (en) | Anti-human bFGF nano antibodies are preparing the application in treating melanoma drug | |
| CN103333247B (en) | Novel monoclonal antibody of VEGFR2 and preparation and application thereof | |
| CN102702324A (en) | Application of human procalcitonin B cell epitope peptide fragment and monoclonal antibody thereof | |
| CN105504057B (en) | Anti- hantaan virus mouse/people's chimeric antibody and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |